Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment of B cell malignancies characterized by constitutive B cell receptor activation, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The efficacy and safety of zanubrutinib,...
Saved in:
| Published in | Journal of hematology and oncology Vol. 13; no. 1; pp. 48 - 12 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
11.05.2020
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment of B cell malignancies characterized by constitutive B cell receptor activation, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
The efficacy and safety of zanubrutinib, an investigational highly selective BTK inhibitor, was evaluated in this single-arm, phase 2 study of Chinese patients with relapsed/refractory CLL/SLL. The primary endpoint was overall response rate as assessed by an independent review committee.
Of the 91 evaluable patients, 77 (84.6%) achieved a response, with three (3.3%), 54 (59.3%), and 20 (22%) patients achieving a complete response, partial response, and partial response with lymphocytosis, respectively, after a median follow-up of 15.1 months. The estimated 12-month event-free rate for duration of response was 92.9%. The most commonly reported grade ≥ 3 adverse events (AEs) were neutropenia (44%), thrombocytopenia (15.4%), lung infection/pneumonia (13.2%), upper respiratory tract infection (9.9%), and anemia (8.8%). The 12-month overall survival rate was 96%. Eight (9.0%) patients discontinued zanubrutinib due to AEs, and seven (8.0%) patients required at least one dose reduction.
Treatment of patients with relapsed/refractory CLL/SLL with zanubrutinib was generally well tolerated and resulted in a high overall response rate, thereby conferring a favorable benefit-risk profile.
Prospectively registered in China public registry (CTR20160890) on December 7, 2016: http://www.chinadrugtrials.org.cn/. Retrospectively registered in ClinicalTrials.gov (NCT03206918) on July 2, 2017. |
|---|---|
| AbstractList | Abstract Background Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment of B cell malignancies characterized by constitutive B cell receptor activation, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Methods The efficacy and safety of zanubrutinib, an investigational highly selective BTK inhibitor, was evaluated in this single-arm, phase 2 study of Chinese patients with relapsed/refractory CLL/SLL. The primary endpoint was overall response rate as assessed by an independent review committee. Results Of the 91 evaluable patients, 77 (84.6%) achieved a response, with three (3.3%), 54 (59.3%), and 20 (22%) patients achieving a complete response, partial response, and partial response with lymphocytosis, respectively, after a median follow-up of 15.1 months. The estimated 12-month event-free rate for duration of response was 92.9%. The most commonly reported grade ≥ 3 adverse events (AEs) were neutropenia (44%), thrombocytopenia (15.4%), lung infection/pneumonia (13.2%), upper respiratory tract infection (9.9%), and anemia (8.8%). The 12-month overall survival rate was 96%. Eight (9.0%) patients discontinued zanubrutinib due to AEs, and seven (8.0%) patients required at least one dose reduction. Conclusion Treatment of patients with relapsed/refractory CLL/SLL with zanubrutinib was generally well tolerated and resulted in a high overall response rate, thereby conferring a favorable benefit-risk profile. Trial registration Prospectively registered in China public registry (CTR20160890) on December 7, 2016: http://www.chinadrugtrials.org.cn/ . Retrospectively registered in ClinicalTrials.gov ( NCT03206918 ) on July 2, 2017. Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment of B cell malignancies characterized by constitutive B cell receptor activation, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The efficacy and safety of zanubrutinib, an investigational highly selective BTK inhibitor, was evaluated in this single-arm, phase 2 study of Chinese patients with relapsed/refractory CLL/SLL. The primary endpoint was overall response rate as assessed by an independent review committee. Of the 91 evaluable patients, 77 (84.6%) achieved a response, with three (3.3%), 54 (59.3%), and 20 (22%) patients achieving a complete response, partial response, and partial response with lymphocytosis, respectively, after a median follow-up of 15.1 months. The estimated 12-month event-free rate for duration of response was 92.9%. The most commonly reported grade [greater than or equai to] 3 adverse events (AEs) were neutropenia (44%), thrombocytopenia (15.4%), lung infection/pneumonia (13.2%), upper respiratory tract infection (9.9%), and anemia (8.8%). The 12-month overall survival rate was 96%. Eight (9.0%) patients discontinued zanubrutinib due to AEs, and seven (8.0%) patients required at least one dose reduction. Treatment of patients with relapsed/refractory CLL/SLL with zanubrutinib was generally well tolerated and resulted in a high overall response rate, thereby conferring a favorable benefit-risk profile. Abstract Background Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment of B cell malignancies characterized by constitutive B cell receptor activation, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Methods The efficacy and safety of zanubrutinib, an investigational highly selective BTK inhibitor, was evaluated in this single-arm, phase 2 study of Chinese patients with relapsed/refractory CLL/SLL. The primary endpoint was overall response rate as assessed by an independent review committee. Results Of the 91 evaluable patients, 77 (84.6%) achieved a response, with three (3.3%), 54 (59.3%), and 20 (22%) patients achieving a complete response, partial response, and partial response with lymphocytosis, respectively, after a median follow-up of 15.1 months. The estimated 12-month event-free rate for duration of response was 92.9%. The most commonly reported grade ≥ 3 adverse events (AEs) were neutropenia (44%), thrombocytopenia (15.4%), lung infection/pneumonia (13.2%), upper respiratory tract infection (9.9%), and anemia (8.8%). The 12-month overall survival rate was 96%. Eight (9.0%) patients discontinued zanubrutinib due to AEs, and seven (8.0%) patients required at least one dose reduction. Conclusion Treatment of patients with relapsed/refractory CLL/SLL with zanubrutinib was generally well tolerated and resulted in a high overall response rate, thereby conferring a favorable benefit-risk profile. Trial registration Prospectively registered in China public registry (CTR20160890) on December 7, 2016: http://www.chinadrugtrials.org.cn/ . Retrospectively registered in ClinicalTrials.gov ( NCT03206918 ) on July 2, 2017. Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment of B cell malignancies characterized by constitutive B cell receptor activation, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The efficacy and safety of zanubrutinib, an investigational highly selective BTK inhibitor, was evaluated in this single-arm, phase 2 study of Chinese patients with relapsed/refractory CLL/SLL. The primary endpoint was overall response rate as assessed by an independent review committee. Of the 91 evaluable patients, 77 (84.6%) achieved a response, with three (3.3%), 54 (59.3%), and 20 (22%) patients achieving a complete response, partial response, and partial response with lymphocytosis, respectively, after a median follow-up of 15.1 months. The estimated 12-month event-free rate for duration of response was 92.9%. The most commonly reported grade ≥ 3 adverse events (AEs) were neutropenia (44%), thrombocytopenia (15.4%), lung infection/pneumonia (13.2%), upper respiratory tract infection (9.9%), and anemia (8.8%). The 12-month overall survival rate was 96%. Eight (9.0%) patients discontinued zanubrutinib due to AEs, and seven (8.0%) patients required at least one dose reduction. Treatment of patients with relapsed/refractory CLL/SLL with zanubrutinib was generally well tolerated and resulted in a high overall response rate, thereby conferring a favorable benefit-risk profile. Prospectively registered in China public registry (CTR20160890) on December 7, 2016: http://www.chinadrugtrials.org.cn/. Retrospectively registered in ClinicalTrials.gov (NCT03206918) on July 2, 2017. Background Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment of B cell malignancies characterized by constitutive B cell receptor activation, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Methods The efficacy and safety of zanubrutinib, an investigational highly selective BTK inhibitor, was evaluated in this single-arm, phase 2 study of Chinese patients with relapsed/refractory CLL/SLL. The primary endpoint was overall response rate as assessed by an independent review committee. Results Of the 91 evaluable patients, 77 (84.6%) achieved a response, with three (3.3%), 54 (59.3%), and 20 (22%) patients achieving a complete response, partial response, and partial response with lymphocytosis, respectively, after a median follow-up of 15.1 months. The estimated 12-month event-free rate for duration of response was 92.9%. The most commonly reported grade ≥ 3 adverse events (AEs) were neutropenia (44%), thrombocytopenia (15.4%), lung infection/pneumonia (13.2%), upper respiratory tract infection (9.9%), and anemia (8.8%). The 12-month overall survival rate was 96%. Eight (9.0%) patients discontinued zanubrutinib due to AEs, and seven (8.0%) patients required at least one dose reduction. Conclusion Treatment of patients with relapsed/refractory CLL/SLL with zanubrutinib was generally well tolerated and resulted in a high overall response rate, thereby conferring a favorable benefit-risk profile. Trial registration Prospectively registered in China public registry (CTR20160890) on December 7, 2016: http://www.chinadrugtrials.org.cn/. Retrospectively registered in ClinicalTrials.gov (NCT03206918) on July 2, 2017. Background Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment of B cell malignancies characterized by constitutive B cell receptor activation, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Methods The efficacy and safety of zanubrutinib, an investigational highly selective BTK inhibitor, was evaluated in this single-arm, phase 2 study of Chinese patients with relapsed/refractory CLL/SLL. The primary endpoint was overall response rate as assessed by an independent review committee. Results Of the 91 evaluable patients, 77 (84.6%) achieved a response, with three (3.3%), 54 (59.3%), and 20 (22%) patients achieving a complete response, partial response, and partial response with lymphocytosis, respectively, after a median follow-up of 15.1 months. The estimated 12-month event-free rate for duration of response was 92.9%. The most commonly reported grade [greater than or equai to] 3 adverse events (AEs) were neutropenia (44%), thrombocytopenia (15.4%), lung infection/pneumonia (13.2%), upper respiratory tract infection (9.9%), and anemia (8.8%). The 12-month overall survival rate was 96%. Eight (9.0%) patients discontinued zanubrutinib due to AEs, and seven (8.0%) patients required at least one dose reduction. Conclusion Treatment of patients with relapsed/refractory CLL/SLL with zanubrutinib was generally well tolerated and resulted in a high overall response rate, thereby conferring a favorable benefit-risk profile. Trial registration Prospectively registered in China public registry (CTR20160890) on December 7, 2016: Keywords: Bruton's tyrosine kinase, Chronic lymphocytic leukemia, Relapsed/refractory, Zanubrutinib, Clinical trial |
| ArticleNumber | 48 |
| Audience | Academic |
| Author | Huang, Jane Ji, Meng Feng, Shibao Li, Jianyong Xu, Wei Zhou, Keshu Hu, Jianda Guo, Haiyi Feng, Ru Yang, Shenmiao Zhou, Daobin Huang, Haiwen Pan, Ling Zhou, Jianfeng Li, Zengjun Novotny, William Gao, Sujun |
| Author_xml | – sequence: 1 givenname: Wei surname: Xu fullname: Xu, Wei organization: Department of Hematology, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China – sequence: 2 givenname: Shenmiao surname: Yang fullname: Yang, Shenmiao organization: Peking University Peoples Hospital, Peking University Institute of Hematology, Beijing, China – sequence: 3 givenname: Keshu surname: Zhou fullname: Zhou, Keshu organization: Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China – sequence: 4 givenname: Ling surname: Pan fullname: Pan, Ling organization: West China Hospital of Sichuan University, Chengdu, China – sequence: 5 givenname: Zengjun surname: Li fullname: Li, Zengjun organization: Blood Disease Hospital, Chinese Academy of Medical Science, Tianjin, China – sequence: 6 givenname: Jianfeng surname: Zhou fullname: Zhou, Jianfeng organization: Tongji Hospital, Tongji Medical College, Wuhan, China – sequence: 7 givenname: Sujun surname: Gao fullname: Gao, Sujun organization: The First Hospital of Jilin University, Changchun, China – sequence: 8 givenname: Daobin surname: Zhou fullname: Zhou, Daobin organization: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China – sequence: 9 givenname: Jianda surname: Hu fullname: Hu, Jianda organization: Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, China – sequence: 10 givenname: Ru surname: Feng fullname: Feng, Ru organization: Nanfang Hospital of Southern Medical University, Guangzhou, China – sequence: 11 givenname: Haiwen surname: Huang fullname: Huang, Haiwen organization: The 1st Hospital of Soochow University, Suzhou, China – sequence: 12 givenname: Meng surname: Ji fullname: Ji, Meng organization: BeiGene USA, Inc., San Mateo, CA, USA – sequence: 13 givenname: Haiyi surname: Guo fullname: Guo, Haiyi organization: BeiGene USA, Inc., San Mateo, CA, USA – sequence: 14 givenname: Jane surname: Huang fullname: Huang, Jane organization: BeiGene USA, Inc., San Mateo, CA, USA – sequence: 15 givenname: William surname: Novotny fullname: Novotny, William organization: BeiGene USA, Inc., San Mateo, CA, USA – sequence: 16 givenname: Shibao surname: Feng fullname: Feng, Shibao organization: BeiGene USA, Inc., San Mateo, CA, USA – sequence: 17 givenname: Jianyong orcidid: 0000-0002-9931-4055 surname: Li fullname: Li, Jianyong email: lijianyonglm@126.com organization: Department of Hematology, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China. lijianyonglm@126.com |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32393328$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkttu1DAQhiNURA_wAlwgS0hcNV2fk3BRqVQcKipxs1xbY8fZuCT2Yieg5Xl4ULy7pXQl5AuPxv98mhn_p8WRD94WxUuCLwip5SIRhrkoMcUlxnXNS_6kOCGVkGVdUXr0KD4uTlO6w1iShuJnxTGjrGGM1ifF72W0MI3WTyh0KNoB1sm2i2i7CGYKcYNMH4N3Bg2bcd0Hs5m2sZ2_2dHBIo0wDIdPu3gE9NNNPZp6i94tPyPne6dd5qFf4Gcd58l5p9-idQ_JInqOkvOrwZYQx3M0zkMm5ZZsRGma283z4mkHQ7Iv7u-z4uuH98vrT-Xtl48311e3pZGcTaWUQLgWrKlb2QADbrQmFhNNmrbqoKMAFZWc6G2K5gUIZoW0jOGq1UJqdlbc7LltgDu1jm6EuFEBnNolQlwpiLm1wapW1sYKayqNO66xqCUY0QhGW9zUQOvMutyz1rMebbsdJ8JwAD188a5Xq_BDVZRIjnEGvL4HxPB9tmlSd2GOPs-vKMecNljw6p9qBbkr57uQYWZ0yagrSSvOORVb1cV_VPm0-RdNdlXncv6g4M2jgt7CMPUpDPnbgk-HQroXmhhSyrZ5mJBgtXWp2rtUZZeqnUsVz0WvHu_moeSvLdkfqtvmnQ |
| CitedBy_id | crossref_primary_10_1021_acsptsci_2c00163 crossref_primary_10_1182_hematology_2020000086 crossref_primary_10_1007_s00277_023_05486_x crossref_primary_10_1080_10428194_2021_1929961 crossref_primary_10_1007_s11864_022_00974_0 crossref_primary_10_1182_hematology_2020000160 crossref_primary_10_1002_ajh_26367 crossref_primary_10_1016_j_blre_2022_100930 crossref_primary_10_1186_s40164_023_00448_5 crossref_primary_10_3389_fimmu_2022_982346 crossref_primary_10_1186_s40364_020_00222_3 crossref_primary_10_2217_fon_2023_0574 crossref_primary_10_3390_pharmaceutics16010055 crossref_primary_10_1080_17425255_2021_1955855 crossref_primary_10_1186_s40164_022_00315_9 crossref_primary_10_1186_s13045_021_01049_7 crossref_primary_10_1016_j_clml_2023_04_006 crossref_primary_10_1182_blood_2023020195 crossref_primary_10_3324_haematol_2020_259432 crossref_primary_10_3389_fonc_2021_720704 crossref_primary_10_1186_s12938_021_00973_6 crossref_primary_10_2147_DDDT_S250823 crossref_primary_10_1097_PPO_0000000000000537 crossref_primary_10_1111_bjh_17994 crossref_primary_10_1007_s11864_022_00953_5 crossref_primary_10_3390_cancers13102468 crossref_primary_10_1016_j_blre_2021_100884 crossref_primary_10_2147_DDDT_S377697 crossref_primary_10_1097_CCO_0000000000000897 crossref_primary_10_17925_OHR_2022_18_1_44 crossref_primary_10_1080_14656566_2022_2144218 crossref_primary_10_1007_s11899_023_00701_y crossref_primary_10_3389_fonc_2021_760405 crossref_primary_10_1016_j_clml_2023_02_001 crossref_primary_10_1182_bloodadvances_2021005621 crossref_primary_10_3389_fonc_2021_780085 crossref_primary_10_1016_S1470_2045_22_00293_5 crossref_primary_10_3389_fphar_2022_995522 crossref_primary_10_3389_fonc_2023_1130595 crossref_primary_10_3390_ph16030400 crossref_primary_10_1016_j_hoc_2021_03_008 crossref_primary_10_1080_14712598_2022_2145881 crossref_primary_10_3389_fcell_2021_630942 crossref_primary_10_1080_14740338_2023_2251376 crossref_primary_10_3389_fmed_2022_833565 crossref_primary_10_1039_D2CS00362G crossref_primary_10_1002_cam4_6009 crossref_primary_10_1080_17474086_2024_2356257 crossref_primary_10_3389_fimmu_2022_894787 crossref_primary_10_3390_cells11142235 crossref_primary_10_1080_10428194_2022_2164692 crossref_primary_10_3389_fphar_2024_1413985 crossref_primary_10_1007_s11684_021_0891_0 crossref_primary_10_1097_CM9_0000000000001811 crossref_primary_10_3390_pharmaceutics13101604 crossref_primary_10_1038_s41408_023_00902_x crossref_primary_10_3389_fimmu_2022_939978 crossref_primary_10_6004_jnccn_2022_0031 crossref_primary_10_1002_ajh_26826 crossref_primary_10_3390_jcm10112516 crossref_primary_10_3390_cancers15071996 crossref_primary_10_1007_s11523_021_00857_8 crossref_primary_10_1002_hon_3145 crossref_primary_10_1007_s10637_023_01376_1 crossref_primary_10_1080_17512433_2021_1978288 crossref_primary_10_1007_s11596_021_2385_3 crossref_primary_10_1210_jcemcr_luad172 crossref_primary_10_3390_cancers16111996 crossref_primary_10_1080_14656566_2023_2229734 crossref_primary_10_1007_s11899_021_00645_1 crossref_primary_10_1007_s12325_022_02238_7 crossref_primary_10_1080_10428194_2022_2098289 crossref_primary_10_1186_s13045_022_01353_w crossref_primary_10_1007_s11864_023_01112_0 crossref_primary_10_1200_OP_23_00770 crossref_primary_10_1080_09537104_2020_1849600 crossref_primary_10_1007_s11899_023_00700_z crossref_primary_10_1080_14740338_2020_1802424 crossref_primary_10_3390_jcm10215104 crossref_primary_10_1080_17474086_2022_2074393 crossref_primary_10_1007_s11899_021_00652_2 crossref_primary_10_3390_curroncol29050264 |
| Cites_doi | 10.1056/NEJMoa1513257 10.1182/blood-2017-10-810044 10.1182/blood.2019001160 10.1093/biomet/26.4.404 10.4103/0366-6999.164918 10.2307/2530286 10.1182/blood-2009-03-212837 10.1056/NEJMoa1400376 10.1182/blood-2014-10-604272 10.1002/hon.54_2629 10.1002/prp2.156 10.1200/JCO.1997.15.2.458 10.1182/blood-2011-11-390989 10.1002/cam4.1337 10.1182/blood-2011-10-386417 10.1182/blood-2019-125394 10.3324/haematol.2017.182907 10.1056/NEJMoa1215637 10.1182/blood-2011-06-338855 10.1097/01.HS9.0000562920.26603.5b 10.1056/NEJMoa1509388 10.1007/s00280-019-04015-w 10.1182/blood-2014-06-583294 10.1200/JCO.2013.54.8800 10.1080/10428194.2018.1460474 10.1038/leu.2017.175 10.1182/blood-2004-07-2669 10.1056/NEJMoa1315226 10.3324/haematol.2017.164103 10.1056/NEJMoa1509981 10.1016/S1470-2045(16)30212-1 10.1111/bjh.14324 10.1016/j.blre.2018.03.004 10.1200/JCO.2012.42.7906 10.1038/leu.2014.247 10.1053/j.seminoncol.2005.12.013 10.1182/blood-2007-06-093906 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2020 BioMed Central Ltd. 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2020 |
| Copyright_xml | – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2020 |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PIMPY PQEST PQQKQ PQUKI PRINS 5PM DOA |
| DOI | 10.1186/s13045-020-00884-4 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts Immunology Abstracts ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) |
| DatabaseTitleList | CrossRef MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1756-8722 |
| EndPage | 12 |
| ExternalDocumentID | oai_doaj_org_article_d68ce5ec7b0f4b0586ac59532d098a28 A627444257 10_1186_s13045_020_00884_4 32393328 |
| Genre | Multicenter Study Clinical Trial, Phase II Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GrantInformation_xml | – fundername: ; |
| GroupedDBID | --- -5E -5G -A0 -BR 0R~ 2WC 3V. 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ ABDBF ABUWG ACGFS ACIHN ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EBD EBLON EBS ECM EIF EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP ~8M AAYXX CITATION AFGXO ABVAZ AFNRJ 7T5 7XB 8FK AZQEC DWQXO H94 K9. PQEST PQUKI PRINS 5PM |
| ID | FETCH-LOGICAL-c643t-66a14b5398d69a3a4cbb1e01b19d7faf2aa72641b01b1293353e56e3307db56b3 |
| IEDL.DBID | RPM |
| ISSN | 1756-8722 |
| IngestDate | Tue Oct 22 15:15:34 EDT 2024 Tue Sep 17 21:22:07 EDT 2024 Thu Oct 10 16:20:24 EDT 2024 Thu Feb 22 23:29:18 EST 2024 Fri Feb 02 04:30:28 EST 2024 Tue Aug 20 22:12:30 EDT 2024 Thu Sep 12 16:33:35 EDT 2024 Sat Sep 28 08:35:48 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Bruton’s tyrosine kinase Clinical trial Chronic lymphocytic leukemia Relapsed/refractory Zanubrutinib |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c643t-66a14b5398d69a3a4cbb1e01b19d7faf2aa72641b01b1293353e56e3307db56b3 |
| ORCID | 0000-0002-9931-4055 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216400/ |
| PMID | 32393328 |
| PQID | 2404290547 |
| PQPubID | 54946 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d68ce5ec7b0f4b0586ac59532d098a28 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7216400 proquest_journals_2404290547 gale_infotracmisc_A627444257 gale_infotracacademiconefile_A627444257 gale_healthsolutions_A627444257 crossref_primary_10_1186_s13045_020_00884_4 pubmed_primary_32393328 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-05-11 |
| PublicationDateYYYYMMDD | 2020-05-11 |
| PublicationDate_xml | – month: 05 year: 2020 text: 2020-05-11 day: 11 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Journal of hematology and oncology |
| PublicationTitleAlternate | J Hematol Oncol |
| PublicationYear | 2020 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | MFM de Rooij (884_CR8) 2012; 119 R Brookmeyer (884_CR27) 1982; 38 JM Sorensen (884_CR25) 1997; 15 884_CR35 JA Burger (884_CR10) 2015; 373 884_CR37 A Petlickovski (884_CR4) 2005; 105 884_CR31 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (884_CR23) 2017 884_CR11 M Hallek (884_CR20) 2008; 111 CS Tam (884_CR43) 2019; 134 JC Byrd (884_CR3) 2013; 369 JR McMullen (884_CR18) 2014; 124 NCI-CTEP (884_CR24) 2010 S Ponader (884_CR7) 2012; 119 AR Mato (884_CR13) 2018; 103 CJ Clopper (884_CR26) 1934; 26 RR Furman (884_CR1) 2014; 370 JR Brown (884_CR36) 2018; 32 MP Quiroga (884_CR6) 2009; 114 T Hilal (884_CR40) 2018; 32 S Mu (884_CR32) 2020; 85 AW Roberts (884_CR2) 2016; 374 JC Byrd (884_CR9) 2014; 371 S O’Brien (884_CR38) 2016; 17 I de Weerdt (884_CR14) 2017; 102 S Swerdlow (884_CR21) 2008 JC Byrd (884_CR29) 2016; 374 RH Advani (884_CR30) 2013; 31 BD Cheson (884_CR22) 2014; 32 X Huang (884_CR39) 2018; 7 884_CR45 884_CR44 CS Tam (884_CR15) 2019; 134 S Kamel (884_CR16) 2015; 29 M Greenwood (884_CR28) 1926 M Levade (884_CR17) 2014; 124 PD Wadhwa (884_CR41) 2006; 33 J de Jong (884_CR33) 2018; 59 FK Stevenson (884_CR5) 2011; 118 C-L Chei (884_CR42) 2015; 128 S O’Brien (884_CR12) 2018; 131 J de Jong (884_CR34) 2015; 3 PA Thompson (884_CR19) 2016; 175 |
| References_xml | – volume: 374 start-page: 311 year: 2016 ident: 884_CR2 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1513257 contributor: fullname: AW Roberts – volume: 131 start-page: 1910 year: 2018 ident: 884_CR12 publication-title: Blood. doi: 10.1182/blood-2017-10-810044 contributor: fullname: S O’Brien – volume-title: Introductory guide: MedDRA version 20.0 year: 2017 ident: 884_CR23 contributor: fullname: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use – volume: 134 start-page: 851 year: 2019 ident: 884_CR15 publication-title: Blood. doi: 10.1182/blood.2019001160 contributor: fullname: CS Tam – volume: 26 start-page: 404 year: 1934 ident: 884_CR26 publication-title: Biometrika. doi: 10.1093/biomet/26.4.404 contributor: fullname: CJ Clopper – volume: 128 start-page: 2426 year: 2015 ident: 884_CR42 publication-title: Chin Med J. doi: 10.4103/0366-6999.164918 contributor: fullname: C-L Chei – volume: 38 start-page: 29 year: 1982 ident: 884_CR27 publication-title: Biometrics. doi: 10.2307/2530286 contributor: fullname: R Brookmeyer – volume: 114 start-page: 1029 year: 2009 ident: 884_CR6 publication-title: Blood. doi: 10.1182/blood-2009-03-212837 contributor: fullname: MP Quiroga – volume: 371 start-page: 213 year: 2014 ident: 884_CR9 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1400376 contributor: fullname: JC Byrd – ident: 884_CR45 – volume: 124 start-page: 3829 year: 2014 ident: 884_CR18 publication-title: Blood. doi: 10.1182/blood-2014-10-604272 contributor: fullname: JR McMullen – ident: 884_CR37 doi: 10.1002/hon.54_2629 – volume: 3 year: 2015 ident: 884_CR34 publication-title: Pharmacol Res Perspect. doi: 10.1002/prp2.156 contributor: fullname: J de Jong – volume: 15 start-page: 458 year: 1997 ident: 884_CR25 publication-title: J Clin Oncol. doi: 10.1200/JCO.1997.15.2.458 contributor: fullname: JM Sorensen – volume: 119 start-page: 2590 year: 2012 ident: 884_CR8 publication-title: Blood. doi: 10.1182/blood-2011-11-390989 contributor: fullname: MFM de Rooij – volume: 7 start-page: 1043 year: 2018 ident: 884_CR39 publication-title: Cancer Med. doi: 10.1002/cam4.1337 contributor: fullname: X Huang – volume: 119 start-page: 1182 year: 2012 ident: 884_CR7 publication-title: Blood. doi: 10.1182/blood-2011-10-386417 contributor: fullname: S Ponader – volume-title: Common terminology criteria for adverse events (CTCAE) year: 2010 ident: 884_CR24 contributor: fullname: NCI-CTEP – ident: 884_CR31 – volume: 134 start-page: 499 issue: Suppl 1 year: 2019 ident: 884_CR43 publication-title: Blood doi: 10.1182/blood-2019-125394 contributor: fullname: CS Tam – volume: 103 start-page: 874 year: 2018 ident: 884_CR13 publication-title: Haematologica. doi: 10.3324/haematol.2017.182907 contributor: fullname: AR Mato – volume: 369 start-page: 32 year: 2013 ident: 884_CR3 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1215637 contributor: fullname: JC Byrd – volume: 118 start-page: 4313 year: 2011 ident: 884_CR5 publication-title: Blood. doi: 10.1182/blood-2011-06-338855 contributor: fullname: FK Stevenson – ident: 884_CR44 doi: 10.1097/01.HS9.0000562920.26603.5b – ident: 884_CR35 – ident: 884_CR11 – volume-title: WHO classification of tumours of haematopoietic and lymphoid tissues year: 2008 ident: 884_CR21 contributor: fullname: S Swerdlow – volume: 373 start-page: 2425 year: 2015 ident: 884_CR10 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1509388 contributor: fullname: JA Burger – volume: 85 start-page: 391 year: 2020 ident: 884_CR32 publication-title: Cancer Chemother Pharmacol. doi: 10.1007/s00280-019-04015-w contributor: fullname: S Mu – volume: 124 start-page: 3991 year: 2014 ident: 884_CR17 publication-title: Blood. doi: 10.1182/blood-2014-06-583294 contributor: fullname: M Levade – volume: 32 start-page: 3059 year: 2014 ident: 884_CR22 publication-title: J Clin Oncol. doi: 10.1200/JCO.2013.54.8800 contributor: fullname: BD Cheson – volume: 59 start-page: 2888 year: 2018 ident: 884_CR33 publication-title: Leuk Lymphoma. doi: 10.1080/10428194.2018.1460474 contributor: fullname: J de Jong – volume-title: A report on the natural duration of cancer year: 1926 ident: 884_CR28 contributor: fullname: M Greenwood – volume: 32 start-page: 83 year: 2018 ident: 884_CR36 publication-title: Leukemia. doi: 10.1038/leu.2017.175 contributor: fullname: JR Brown – volume: 105 start-page: 4820 year: 2005 ident: 884_CR4 publication-title: Blood. doi: 10.1182/blood-2004-07-2669 contributor: fullname: A Petlickovski – volume: 370 start-page: 997 year: 2014 ident: 884_CR1 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1315226 contributor: fullname: RR Furman – volume: 102 start-page: 1629 year: 2017 ident: 884_CR14 publication-title: Haematologica. doi: 10.3324/haematol.2017.164103 contributor: fullname: I de Weerdt – volume: 374 start-page: 323 year: 2016 ident: 884_CR29 publication-title: N Engl J Med. doi: 10.1056/NEJMoa1509981 contributor: fullname: JC Byrd – volume: 17 start-page: 1409 year: 2016 ident: 884_CR38 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30212-1 contributor: fullname: S O’Brien – volume: 175 start-page: 462 year: 2016 ident: 884_CR19 publication-title: Br J Haematol. doi: 10.1111/bjh.14324 contributor: fullname: PA Thompson – volume: 32 start-page: 387 year: 2018 ident: 884_CR40 publication-title: Blood Rev. doi: 10.1016/j.blre.2018.03.004 contributor: fullname: T Hilal – volume: 31 start-page: 88 year: 2013 ident: 884_CR30 publication-title: J Clin Oncol. doi: 10.1200/JCO.2012.42.7906 contributor: fullname: RH Advani – volume: 29 start-page: 783 year: 2015 ident: 884_CR16 publication-title: Leukemia. doi: 10.1038/leu.2014.247 contributor: fullname: S Kamel – volume: 33 start-page: 240 year: 2006 ident: 884_CR41 publication-title: Semin Oncol. doi: 10.1053/j.seminoncol.2005.12.013 contributor: fullname: PD Wadhwa – volume: 111 start-page: 5446 year: 2008 ident: 884_CR20 publication-title: Blood. doi: 10.1182/blood-2007-06-093906 contributor: fullname: M Hallek |
| SSID | ssj0061920 |
| Score | 2.5618289 |
| Snippet | Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment of B cell malignancies characterized by constitutive B... Abstract Background Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment of B cell malignancies characterized... Background Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment of B cell malignancies characterized by... Abstract Background Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment of B cell malignancies characterized... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 48 |
| SubjectTerms | Adult Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors Aged Aged, 80 and over Anemia Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Bronchopulmonary infection Bruton's tyrosine kinase Cardiac arrhythmia Cell activation Cell adhesion & migration China - epidemiology Chronic lymphocytic leukemia Clinical medicine Clinical trial Clinical trials Confidence intervals Consent Deoxyribonucleic acid DNA Drug therapy Female Growth factors Health aspects Hematology Hepatitis Humans Ibrutinib Idelalisib Infections Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology Lymphatic leukemia Lymphocytosis Lymphoma Lymphomas Male Medical research Middle Aged Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - epidemiology Neutropenia Oncology Piperidines - adverse effects Piperidines - therapeutic use Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Protein-tyrosine kinase Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use Receptor mechanisms Relapsed/refractory Respiratory tract diseases Studies Thrombocytopenia Treatment Outcome Tyrosine Venetoclax Zanubrutinib |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9MwGLbQDogL4puOAT4gcWBW4zh2kt02xDSBxqmTdrNef0SNaNMqbQ_l9_BD99pJqkYcuHCzbEuJ_X49_ngfE_IpSUzuM1WxpFIJyySkDIRTTAAHjq7Sysgze_tT3dxl3-_l_dFTX-FOWEcP3E3c1KnCeultbpIqM4ksFFhZSpG6pCwg7dJ8k3JYTHU-OKwKkiFFplDTDQ8HgiwslTDmFRnLRmEosvX_7ZOPgtL4wuRRBLp-Rp720JFedr_8nDzyzQvy-LY_HH9J_syGS-N0VdGQpLLeeDfFb7fxUZ09tR0TLl3sUYYru9-Gst_98ssappslLBbjplheAg2btRSRIr2a_aB1M68N-oGW_oZmZ1rU3KY2F3Q9x4BI03Madh8WnkG7PKfxvmIYj29pZLJ9Re6uv82-3rD-EQZmEaxsmVLAMyNFWThVgoDMGsN9wg0vXV5BlQLkCKq4CVWIHYQUXiov0Hc4I5URr8lJs2r8W0JTLiorTOnz0iBukcYBVNI5JwtQlbUT8mWQiV53XBs6rlEKpTsJapSgjhLU2YRcBbEdegae7FiB2qN77dH_0p4J-RiErruk04O168vwJFEW_NmEfI49gr2j7C30aQs4pMCcNep5NuqJdmrHzYNi6d5PbDTiKQQECJux-U2nY4cBicBOJ8I_5iPtG4143NLU88gQHhiZ0Dmf_o8pekeepNFwJOP8jJxs251_j0Bsaz5Em3sAmrIzWA priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9NAEF5BKiEuiDdpC-wBiQNdxfZ61zYX1KBWFagVQqnU22pfbiISJzjJIfwefigzazvUQuJmeVeyV9_MN7Ovbwh5F0Um86ksWVTKiKVCJ0xzJxnXsY6BKq0IOrOXV_LiOv1yI27aBbd1e6yy48RA1G5pcY18BJEHqBMSjOzT6ifDqlG4u9qW0LhPDhKYKUQDcjA-u_r2veNinB1E3VWZXI7WMW4MMpwyQezLU5b2wlFQ7f-Xm-8Ep_7ByTuR6PwxedSmkPS0wfwJueerp-TBZbtJ_oz8nnSHx-mypHhZZbX2bgTfrkNxnR21jSIune8Ay6XdbfDZb3_4xUyP1gs9n_ebwvNCU1y0pZAx0vHkK51V05kBPqjpL11tTQ0WXM3MR7qaQmCkyQnFVYi5Z7penNBwbhHH42saFG2fk-vzs8nnC9YWY2AWkpYNk1LHqRG8yJ0sNNepNSb2UWziwmWlLhOtM0iuYoOvIIfggnshPQcOcUZIw1-QQbWs_CtCk5iXlpvCZ4WB_EUYp3UpnHMi17K0dkg-dJioVaO5ocJcJZeqQVABgiogqNIhGSNs-56olx1eLOtb1bqfcjK3XnibmahMTSRyqa0oBE9cVOQ6yYfkLYKumsune69Xp1iaKEVeG5L3oQf6PWBvdXt9AYaEClq9nse9nuCvtt_cGZZq-WKt_lr3kLxsbGw_II4qdRz_MetZX2_E_ZZqNg1K4ajMBG5x-P9PHpGHSXAJweL4mAw29da_hlRrY960_vQHn1Ar_A priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1bb9MwFLbGkKa9IO4UBvgBiQdmGseXJEgIbYhpAo2nVtqb5VvWijYtaStRfg8_lGMnqRox3qLYSeSc23d8-Q5Cb5LEZJ7LkiSlTAgXOiWaOUmYppqCq7Qi8sxefZeXY_71WlwfoK7cUfsDV7emdqGe1Lievf_1c_sJDP5jNPhcDlc0LPeRkAhBRMs54XfQ3ZRDph628vHdqkLIFZLu4Mytzx2jIxY4wVgozr4XpyKd_79Oey9q9XdU7oWoi_voXost8VmjDA_Qga8eoqOrdvX8Efoz6naV40WJwymW5cq7IXy7jlV3ttg2VLl4tgUhL-x2Ha795oefT_VwNdezWb8pXs81DrO5GKAkPh99w9NqMjXgKGr8W1cbU4NqV1PzAS8nEDFxeorD9MTME13PT3Hc0BjG42scqW4fo_HFl9HnS9JWaSAW0MyaSKkpN4IVuZOFZppbY6hPqKGFy0pdplpngLqoCbcAXDDBvJAepJM5I6RhT9Bhtaj8M4RTykrLTOGzwgCwEcZpXQrnnMi1LK0doHedTNSyIeNQMYnJpWqEqUCYKgpT8QE6D2Lb9QxE2vHGor5RrV0qJ3PrhbeZSUpuEpFLbUUhWOqSItdpPkCvg9BVcyp15w7UWahZxIPDG6C3sUdQUZC91e25BhhSoNbq9Tzp9QRDtv3mTrFUZwcKABcgBsDV0Py00bHdgDpVHaCsp329EfdbqukkUogHyibw3s__-84X6DiNhiEIpSfocF1v_EuAX2vzKtrUX2rrLaQ priority: 102 providerName: Scholars Portal |
| Title | Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32393328 https://www.proquest.com/docview/2404290547 https://pubmed.ncbi.nlm.nih.gov/PMC7216400 https://doaj.org/article/d68ce5ec7b0f4b0586ac59532d098a28 |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Nb9MwFLe2ISEuiG8Ko_iAxIFliePYSbi106apqNMEndSbZTsOjWjSKm0P5e_hD-XZSapG3Li0Uewqtd7Xz857v4fQpyBQsYl47gU5D7yIydCTNOMelUQScJWaOZ7Z6R2_fYgmczY_QayrhXFJ-1oVl9WyvKyKhcutXJfa7_LE_PvplSWcAd3zT9EpKGi3RW_cr90QBF11TML9DbHvAj27S4Jwl0Se7cRDLfEXtR3Yj4KR4-z_1zMfhaZ-2uRRHLp5hp62ABKPmj_6HJ2Y6gV6PG1fkb9Ef2Zd6jhe5diWqqw3JvPh2bVrrbPHuuHDxcs9SHKl91t7bXa_TFlIf1PK5bI_5K5Lie2RLQa8iMezb7ioFoUCb1Dj37LaqRr0tyrUV7xeQFjE4QW2ZxBL48m6vMAua9Gux9TY8dm-Qg8317OrW69txeBpgCxbj3NJIsVommQ8lVRGWiliAqJImsW5zEMpY4BWRNlbgCAoo4ZxQ8GDZIpxRV-js2pVmbcIh4TmmqrUxKkC9MJUJmXOsixjieS51gP0pZOJWDeMG8LtVBIuGmEKEKZwwhTRAI2t2A4zLVu2u7Gqf4pWZ0TGE22Y0bEK8kgFLOFSs5TRMAvSRIbJAH20QhdN6enB5sXINiaKrFcboM9uhrV6kL2WbfECLMnyZ_VmnvdmgrXq_nCnWKL1FhsBqApgAYBnGH7T6NhhQZ2qDlDc077eivsjYDaOJ7w1k3f__cv36EnoDId5hJyjs229Mx8Ag23VECxvHg_Ro9Fo8mMC3-Pru_vvQ3eiAZ_TKBk6q_wLQmI5ZA |
| link.rule.ids | 230,315,730,783,787,867,888,2109,12068,21400,24330,27936,27937,31731,33756,43322,43817,53804,53806 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLZgk4AXxHUUBvMDEg_MahzHTsILWtGmwtYKoU7am-VbaEWblrR9KL-HH4qPk5RFSLxFsaXE-s75zvHtOwi9jSKdukQUJCpERBKuYqKYFYQpqqinSsODzuxoLIbXyZcbftMsuK2bY5UtJwaitksDa-R9H3k8dfoEI_24-kmgahTsrjYlNO6iQ5Cq8pOvw8H5-Ou3lothdhC1V2Uy0V9T2BgkMGXysS9LSNIJR0G1_19uvhWcugcnb0Wii0foYZNC4rMa88fojiufoHujZpP8Kfo9aQ-P42WB4bLKau1s33-7CsV1dtjUirh4vvNYLs1uA89u-8MtZqq_Xqj5vNsUnhcKw6It9hkjHkwu8ayczrTngwr_UuVWV96Cy5n-gFdTHxhxfIphFWLuiKoWpzicW4TxuAoHRdtn6PrifPJpSJpiDMT4pGVDhFA00ZzlmRW5YioxWlMXUU1zmxaqiJVKfXJFNbzyOQTjzHHhmOcQq7nQ7Dk6KJele4FwTFlhmM5dmmufv3BtlSq4tZZnShTG9ND7FhO5qjU3ZJirZELWCEqPoAwIyqSHBgDbvifoZYcXy-q7bNxPWpEZx51JdVQkOuKZUIbnnMU2yjMVZz10AqDL-vLp3uvlGZQmSoDXeuhd6AF-77E3qrm-4IcEClqdnsednt5fTbe5NSzZ8MVa_rXuHjqqbWw_IAYqdQz-Me1YX2fE3ZZyNg1K4aDM5En65f8_eYLuDyejK3n1eXz5Cj2Ig3twQukxOthUW_fap10b_abxrT8FOi72 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BkSouvCmBQveAxIE6fqx3bXNrC1GhpOohlSouq32ZWI2dyEkO6e_hhzK7tqMYbr1Z3slh4m--mbVnv0HoYxDIxMQs94KcBV5MReQJoplHRChCoEpFnc7s-JKdX8c_bujNzqgv17SvZDGsZuWwKqaut3JRKr_rE_OvxmdWcAaw5y907j9EjyBmA9Zt1BsSttuCoDsjkzJ_Gdovgp7dK0HSS2PPzuMhVv6L2DnsOynJKff_z887CarfPLmTjUZP0a_Oj6YJ5Xa4XsmhuvtH4vFejj5DT9oaFZ80Js_RA1O9QPvj9iv8S_Rn0nWn43mO7WmYxdJoHxyr3fSeDVaN5C6ebQAsc7VZ2WuzvjVlIfxlKWaz_pK7LgW2b4UxlKT4dHKBi2paSCCcGt-Jai1rCJGqkF_wYgqZF0fH2L7mmBlP1OUxdo2R9s8yNXaSua_Q9ejb5Ozca6c9eAqqopXHmAhjSUmWapYJImIlZWiCUIaZTnKRR0IkUL2F0t6CIoVQYigzBEhKS8okeY32qnll3iAchSRXRGYmySQUSFRqIXKqtaapYLlSA_S5e-B80Yh6cLcZShlvkMIBKdwhhccDdGoxsbW0gtzuxrz-zdunxTVLlaFGJTLIYxnQlAlFM0oiHWSpiNIBOrKI4s3p1i2t8BM7-yi2xDlAn5yFJRYAlhLt-QhwyUp09SwPe5ZACKq_3KGWt4S05FC4QeUB9TksHzQA3jrUxcEAJT1o9zzurwBgnRR5C9C39_7lEdq_-jriP79fXrxDjyMXoNQLw0O0t6rX5j1UfCv5wcX2X5vnV_I |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+of+relapsed%2Frefractory+chronic+lymphocytic+leukemia%2Fsmall+lymphocytic+lymphoma+with+the+BTK+inhibitor+zanubrutinib%3A+phase+2%2C+single-arm%2C+multicenter+study&rft.jtitle=Journal+of+hematology+and+oncology&rft.au=Xu%2C+Wei&rft.au=Yang%2C+Shenmiao&rft.au=Zhou%2C+Keshu&rft.au=Pan%2C+Ling&rft.date=2020-05-11&rft.eissn=1756-8722&rft.volume=13&rft.issue=1&rft.spage=48&rft_id=info:doi/10.1186%2Fs13045-020-00884-4&rft_id=info%3Apmid%2F32393328&rft.externalDocID=32393328 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-8722&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-8722&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-8722&client=summon |